Q-omics provides the consensus-scored ATP8B5P profile across patient tissues and cancer cell-line models. ATP8B5P expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP8B5P is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, ATP8B5P RNA expression shows 16,945 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where ATP8B5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP8B5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP8B5P survival associations across molecular data types. ATP8B5P RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP8B5P RNA expression–survival associations across cancer types. High ATP8B5P expression shows unfavorable associations in KIRC, ACC, LIHC and LGG, but favorable associations in UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP8B5P RNA expression.
This table summarizes ATP8B5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ATP8B5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP8B5P shows lower tumor expression in LUAD, KICH and LUSC and higher tumor expression in HNSC, LIHC and STAD. The LUAD box plot shows higher ATP8B5P RNA expression in normal versus tumor tissue (log2 FC = −0.874, t-test p < 0.001).
This table shows molecular features associated with ATP8B5P in patient tissues and cancer cell lines. In patient samples, ATP8B5P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP8B5P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
